TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Periodontal Therapy on Preterm Birth
Brief Summary: The purpose of this study is to determine if non-surgical periodontal (gum) treatment can reduce the incidence of preterm birth and low birth weight babies in mothers with periodontitis (gum disease).


Options:
A: Arm Label: Periodontal Treatment; Type: EXPERIMENTAL; Interventions: Other: multi-center, randomized, controled periodontal therapy | Intervention Type: OTHER; Name: multi-center, randomized, controled periodontal therapy; Assigned to Arm(s): Periodontal Treatment
B: Arm Label: Scaling and root planing; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Periodontal scaling and root planing, Procedure: Scaling and root planing | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Periodontal scaling and root planing; Assigned to Arm(s): Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): Scaling and root planing
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Scaling and root planing | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): 1, 2
D: Intervention Type: PROCEDURE; Name: Treatment of periodontal disease; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Black Cohosh and Red Clover Efficacy for the Relief of Menopausal Symptoms
Brief Summary: This Phase II study, a follow-up to a Phase I trial in normal volunteers, will determine the efficacy of black cohosh and red clover for the relief of menopausal symptoms. It will also assess the safety of chronic dosing (1 year) by evaluating uterine (endometrial biopsies), breast (mammography), and hematology parameters (CBC and chemistry lab values) at baseline and 1 year.


Options:
A: Intervention Type: DRUG; Name: Cimicifuga racemosa; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Trifolium pratense; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Black cohosh; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Red clover; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Black cohosh; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation + dietary soy counseling; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Conjugated equine estrogen +/- medroxyprogesterone acetate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Soy isoflavones | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.


Options:
A: Arm Label: All patients; Type: N/A; Interventions: N/A
B: Arm Label: vitamin D3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): vitamin D3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Tamoxifen; Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Tamoxifen | Arm Label: T+OFS; Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Tamoxifen, Drug: Triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: Exemestane, Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Triptorelin | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): E+OFS | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: PROCEDURE; Name: Oophorectomy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): T+OFS, Tamoxifen | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): E+OFS, T+OFS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)
B: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
C: Arm Label: All patients; Type: N/A; Interventions: N/A
D: Arm Label: Tamoxifen; Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Tamoxifen | Arm Label: T+OFS; Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Tamoxifen, Drug: Triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: Exemestane, Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Triptorelin | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): E+OFS | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: PROCEDURE; Name: Oophorectomy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): T+OFS, Tamoxifen | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): E+OFS, T+OFS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.


Options:
A: Arm Label: T+OFS; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: exemestane, Drug: triptorelin | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): E+OFS | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): T+OFS | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): E+OFS, T+OFS
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: tamoxifen citrate | Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Tamoxifen, then letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Arm Label: Letrozole, then tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole, Letrozole, then tamoxifen, Tamoxifen, then letrozole | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): Letrozole, then tamoxifen, Tamoxifen, Tamoxifen, then letrozole

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.


Options:
A: Arm Label: Tamoxifen; Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Tamoxifen | Arm Label: T+OFS; Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Tamoxifen, Drug: Triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: Exemestane, Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Triptorelin | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): E+OFS | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: PROCEDURE; Name: Oophorectomy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): T+OFS, Tamoxifen | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): E+OFS, T+OFS
B: Arm Label: All patients; Type: N/A; Interventions: N/A
C: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
D: Arm Label: T+OFS; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: exemestane, Drug: triptorelin | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): E+OFS | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): T+OFS | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): E+OFS, T+OFS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma
Brief Summary: RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.

PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.


Options:
A: Arm Label: LDE225 200 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Arm Label: LDE225 800 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Intervention Type: DRUG; Name: LDE225; Assigned to Arm(s): LDE225 200 mg, LDE225 800 mg
B: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
C: Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard surgery | Arm Label: Mohs; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mohs micrographic surgery | Intervention Type: PROCEDURE; Name: standard surgery; Assigned to Arm(s): standard surgery | Intervention Type: PROCEDURE; Name: Mohs micrographic surgery; Assigned to Arm(s): Mohs
D: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma
Brief Summary: RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.

PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Office visit | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Evisit | Intervention Type: OTHER; Name: Evisit; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Office visit; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
C: Arm Label: Skin cancer screening; Type: OTHER; Interventions: Other: Inspection of covered areas | Intervention Type: OTHER; Name: Inspection of covered areas; Assigned to Arm(s): Skin cancer screening
D: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma
Brief Summary: RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.

PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.


Options:
A: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
B: N/A
C: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
D: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma
Brief Summary: RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.

PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.


Options:
A: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
B: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
C: N/A
D: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma
Brief Summary: RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.

PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.


Options:
A: Arm Label: Skin cancer screening; Type: OTHER; Interventions: Other: Inspection of covered areas | Intervention Type: OTHER; Name: Inspection of covered areas; Assigned to Arm(s): Skin cancer screening
B: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
C: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma
Brief Summary: RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.

PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.


Options:
A: N/A
B: Arm Label: RCM-OSS procedure; Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): RCM-OSS procedure | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): RCM-OSS procedure, Standard of care procedure
C: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
D: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions

Answer: C